Thanks to visit codestin.com
Credit goes to xmed.jmir.org

JMIRx Med

PubMed-indexed overlay journal for preprints with post-review manuscript marketplace (What is JMIRx?).

Editor-in-Chief:

Edward Meinert, MA (Oxon), MSc, MBA, MPA, MPH, PhD, CEng, FBCS, EUR ING, Professor of Digital Health and Clinical Artificial Intelligence, Newcastle University, United Kingdom


JMIRx Med (ISSN 2563-6316), which has been accepted for indexing in PubMed and PubMed Central, is an innovative overlay journal to  MedRxiv and JMIR Preprints (other preprint servers are invited to join). JMIRx peer-reviews preprints and publishes their revised "version of record" with peer-review reports across a broad range of medical, clinical and related health sciences. Unlike the majority of JMIR journals, papers published in this journal do not require a digital health focus - in fact, most papers we published in the first months of the journal were related to COVID19, but we publish all research that qualifies for preprinting on MedRxiv

Conceived to address the urgent need to make highly relevant scientific information available as early as possible without losing the quality of the peer-reviewed process, this innovative new journal is the first in a new series of “superjournals”. Superjournals (a type of "overlay" journal) sit on top of preprint servers (JMIRx-Med serves MedRxiv and JMIR Preprints), offering peer-review and everything else a traditional scholarly journal does. Our goal is to rapidly peer review and publish a paper. All JMIRx Med papers must have originated as a preprint. 

All JMIRx Med papers are rigorously peer-reviewed, copyedited and XML-tagged. Accepted papers are published along with the related Peer Review Reports and Author Responses to Peer Review Reports, providing an additional layer of transparency to the scholarly publishing process. 

There is no Article Processing Fee directly paid by authors for this journal. JMIRx Med is envisioned as a diamond open access and Plan-P compliant journal, which enables Plan P member universities/institutions and funders to subsidize peer review of preprints and publishing in JMIRx Med. Individual PI-led labs, departments and universities can become institutional members, guaranteeing unlimited peer-review of preprints.

If you are not affiliated with a Plan P member organization, we encourage you to provide Plan P membership details to your administrator or sign up for a Principal Investigator (PI) level membership. Further details provided here.

For a limited time only, authors who opt-in during submission to receive PREreview or PeerRef community peer review for their preprint or refer us to their department head/librarian/funder contact will receive a membership-waiver and may publish the preprint in JMIRx Med at no cost to the author. Referral form provided here.

To submit a preprint to JMIRx, authors can self-nominate their existing preprints for publication (which is the equivalent to a traditional journal submission), using the minimalistic JMIRx-Med submission form that essentially only points to the preprint (the preprint needs to be unpublished and should not be under consideration by a journal).

 

Preprints that have already been peer-reviewed by third-party Plan P accredited peer-review services such as PREreview and PeerRef do not require further peer-review (at the editors' discretion). In the submission process, you can nominate your preprint for a PREreview journal club, which can be used in lieu of traditional peer-review.

 

For more details on other submission pathways (including for papers not in MedRxiv) and peer-review options see How to submit to a JMIRx journal.

For more information on JMIRx please also see our Knowledge Base article "What is JMIRx?".  

 

 

Recent Articles

Article Thumbnail
#xPharmacologyandTherapeutics

Consumer-level drug recalls usually require action by individual patients. FDA has public-facing outlets to inform the public about drug safety information including all recalls, but individual consumers may not be aware of them. And there is no system in place to notify individual prescribers which of their patients are affected by a specific recall.

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Automating Individualized Notification of Drug Recalls to Patients: Complex Challenges and Qualitative Evaluation"

|
Article Thumbnail
Authors' Responses to Peer-Reviews

This is the author(s)' response to peer review reports related to "Automating Individualized Notification of Drug Recalls to Patients: Complex Challenges and Qualitative Evaluation"

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Automating Individualized Notification of Drug Recalls to Patients: Complex Challenges and Qualitative Evaluation"

|
Article Thumbnail
Authors' Responses to Peer-Reviews

This is the author(s)' response to peer review reports related to "Evaluating the financial factors influencing Maternal, Newborn, and Child Health in Africa: application DEA and Tobit Regression"

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Evaluating the financial factors influencing Maternal, Newborn, and Child Health in Africa: application DEA and Tobit Regression"

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Evaluating the financial factors influencing Maternal, Newborn, and Child Health in Africa: application DEA and Tobit Regression"

|
Article Thumbnail
#xHealthSystemsandQualityImprovement

Despite international efforts, maternal, newborn, and child health (MNCH) outcomes in Africa continue to lag due to inefficient health systems and underperforming financial frameworks. Financial factors—such as total health expenditure, health coverage indices, and spending per capita—are key but understudied drivers of MNCH service efficiency.

|
Article Thumbnail
#xHealthInformatics

Large Language Models (LLMs) have shown promise in therapeutic decision-making comparable to medical experts, but these studies have used highly curated patient data.

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Assessing the Limitations of Large Language Models in Clinical Practice Guideline-concordant Treatment Decision-making on Real-world Data"

|
Article Thumbnail
Authors' Responses to Peer-Reviews

This is the author(s)' response to peer review reports related to "Assessing the Limitations of Large Language Models in Clinical Practice Guideline-concordant Treatment Decision-making on Real-world Data"

|
Article Thumbnail
Peer Reviews

This is a peer review report related to "Assessing the Limitations of Large Language Models in Clinical Practice Guideline-concordant Treatment Decision-making on Real-world Data"

|

Preprints Open for Peer Review

There are no preprints available for open peer-review at this time. Please check back later.

We are working in partnership with